Top Markets
Coin of the day
Arch Biopartners Inc. Arch Biopartners Inc.

Arch Biopartners Inc.

ARCH
Classifica tra le azioni #25412
Arch Biopartners Inc. is a biotechnology firm dedicated to devising... Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Prezzo delle azioni
$0.73393689
Ultima sincronizzazione: 2026-08-20
Capitalizzazione di mercato
$49.86M
Variazione (1 giorno)
-8.26%
Variazione (1 anno)
-38.15%
Paese
CA
Scambia Arch Biopartners Inc. (ARCH)

Categoria

EPS per Arch Biopartners Inc. (ARCH)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Arch Biopartners Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per Arch Biopartners Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$-7.98 -
US